A detailed history of Sws Partners transactions in Guardant Health, Inc. stock. As of the latest transaction made, Sws Partners holds 83,762 shares of GH stock, worth $2.73 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares
83,762
Previous 78,857 6.22%
Holding current value
$2.73 Million
Previous $2.28 Million 15.68%
% of portfolio
0.62%
Previous 0.69%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$22.3 - $36.29 $109,381 - $178,002
4,905 Added 6.22%
83,762 $1.92 Million
Q2 2024

Jul 17, 2024

BUY
$16.07 - $31.84 $537,477 - $1.06 Million
33,446 Added 73.65%
78,857 $2.28 Million
Q1 2024

Apr 30, 2024

SELL
$17.13 - $26.91 $9,592 - $15,069
-560 Reduced 1.22%
45,411 $936,000
Q4 2023

Feb 13, 2024

SELL
$21.58 - $29.5 $15,623 - $21,358
-724 Reduced 1.55%
45,971 $1.24 Million
Q3 2023

Nov 09, 2023

BUY
$25.8 - $39.97 $68,705 - $106,440
2,663 Added 6.05%
46,695 $1.38 Million
Q2 2023

Aug 17, 2023

SELL
$20.94 - $38.01 $56,265 - $102,132
-2,687 Reduced 5.75%
44,032 $1.58 Million
Q2 2023

Aug 10, 2023

BUY
$20.94 - $38.01 $56,265 - $102,132
2,687 Added 6.1%
46,719 $1.67 Million
Q2 2023

Jul 26, 2023

SELL
$20.94 - $38.01 $9,632 - $17,484
-460 Reduced 1.03%
44,032 $1.58 Million
Q1 2023

May 09, 2023

BUY
$22.92 - $33.76 $77,721 - $114,480
3,391 Added 8.25%
44,492 $1.04 Million
Q4 2022

Jan 30, 2023

BUY
$25.44 - $59.78 $245,903 - $577,833
9,666 Added 30.75%
41,101 $1.12 Million
Q3 2022

Nov 09, 2022

BUY
$43.66 - $61.0 $260,650 - $364,170
5,970 Added 23.44%
31,435 $1.69 Million
Q2 2022

Jul 28, 2022

BUY
$28.82 - $77.35 $301,658 - $809,622
10,467 Added 69.79%
25,465 $1.03 Million
Q1 2022

May 05, 2022

BUY
$48.25 - $100.49 $723,653 - $1.51 Million
14,998 New
14,998 $995,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.34B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Sws Partners Portfolio

Follow Sws Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sws Partners, based on Form 13F filings with the SEC.

News

Stay updated on Sws Partners with notifications on news.